In this Corporate Symposium, the learner will demonstrate greater competence in overcoming barriers related to effective insulin use in T2D management. New insulin + GLP-1 receptor agonist combination therapies have the potential to revolutionize diabetes management. When available, clinicians—especially diabetes educators—will be required to have a deep understanding of the clinical safety and efficacy these new products so they can educate patients appropriately.